Nordson Corporation delivered solid results for the fourth quarter and fiscal year 2025, achieving record sales of $2.8 billion (up 4% year-over-year) and record adjusted EPS of $10.24 (up 5%). Q4 sales increased 1% to $752 million, with adjusted EPS growing 9% to $3.03, driven by record EBITDA of $256 million (34% margin) and robust free cash flow conversion of 128%. Performance was bolstered by the successful integration of Atrion Medical and the strategic divestiture of the medical contract manufacturing business, which immediately improved margins. While organic sales faced headwinds from polymer processing and automotive markets, management emphasized these areas have 'troughed.' For fiscal 2026, the company guides for sales growth of 1% to 6% and adjusted EPS growth of 6% to 12%, reflecting confidence in normalized demand and continued execution of the Ascend Strategy.
| Metric | Value | Change |
|---|---|---|
| Q4 Sales | $752 million | +1% |
| Q4 Adjusted EPS | $3.03 | +9% |
| Q4 EBITDA Margin | 34% | +160 bps |
| FY 2025 Sales | $2.8 billion | +4% |
| FY 2025 Adjusted EPS | $10.24 | +5% |
| FY 2025 EBITDA | $900 million | +6% |
| FY 2025 Free Cash Flow | $661 million | 136% of net income |
| Net Debt Leverage | 2.1x | Reduction from start of year |
Nordson is actively optimizing its portfolio through disciplined M&A and divestitures to enhance profitability. The divestiture of the medical contract manufacturing business immediately drove margin expansion in the Medical and Fluid Solutions segment, which saw EBITDA margins jump to 40% in Q4. Management stated, 'The integration of Atrion Medical has been a success... We also strengthened our medical portfolio through the divestiture of our contract manufacturing business, driving immediate improvement in our margins.' This signals a strategic pivot toward higher-margin, differentiated product lines.
The company is witnessing a significant stabilization in its core industrial end markets. Management explicitly stated that the headwinds in polymer processing and automotive markets have 'troughed' and are no longer expected to be a drag on results. CEO Sundaram Nagarajan noted, 'For polymer processing... we're at the bottom and our expectation is, going into the year, that things improve from where we are.' This removal of prior headwinds positions the Industrial Precision Solutions segment for a return to growth.
Nordson's 'Ascend Strategy' and 'NBS Next' framework are driving consistent margin expansion and operational efficiency. The company achieved a record EBITDA of $900 million for fiscal 2025, representing a 32% margin, up from 27% five years prior. CFO Daniel Hopgood highlighted, 'This reflects a full year incremental EBITDA margin of 49% and marks the fifth consecutive year that the Ascend Strategy has delivered strong EBITDA growth.' The focus is now shifting to 'commercial excellence' to sustain this trajectory.
The Advanced Technology Solutions (ATS) segment is poised to benefit from robust secular trends in semiconductors, particularly in AI and cloud computing. Management noted that semiconductor applications account for approximately 50% of ATS revenue and that they are 'winning share based on our ability to deliver innovative new products in short lead times.' Despite near-term softness in x-ray systems due to automotive exposure, the underlying momentum in semi dispense remains a key growth driver.
Capital allocation remains a core pillar of shareholder value creation, supported by strong free cash flow generation. With a leverage ratio of 2.1x and record free cash flow of $661 million, Nordson repurchased $300 million in shares and increased dividends for the 62nd consecutive year. CFO Daniel Hopgood affirmed, 'You're going to continue to see us not just do one or the other, but continue to do both, meaning returning cash to shareholders and continuing to identify and bring in high-quality assets to the portfolio.'
The fiscal 2026 sales guidance range of 1% to 6% implies a cautious outlook, with the low end suggesting essentially flat growth. Despite management's commentary that headwinds have 'troughed,' the guidance implies they do not expect a rapid rebound in industrial activity. CFO Daniel Hopgood explained the low end is a 'hypothetical' downside scenario, but the wide range suggests visibility remains limited regarding the pace of the recovery.
While the Medical segment posted exceptional 40% EBITDA margins in Q4, management cautioned that this level is not sustainable. CFO Daniel Hopgood stated, 'I don't know that 40% plus is the right way to think about it. I think we're very comfortable maintaining the upper 30s in our medical business.' Investors should model for a normalization of margins in this segment moving forward.
The Advanced Technology Solutions (ATS) segment faced weakness in Q4, with sales down 4% and EBITDA margins contracting 200 basis points to 25%. Management attributed this to 'weakness in x-ray systems demand' and 'unfavorable product mix.' While semiconductor demand is strong, the reliance on lumpy system deliveries and exposure to automotive markets creates volatility and potential execution risk.
Full year organic sales decreased roughly 3% in fiscal 2025, weighed down by specific end markets. While management attributes this to macro factors, the lack of organic top-line growth highlights the company's sensitivity to industrial cycles and the challenge of growing revenue in a slowing economy, even with a strong portfolio.
Overall: Management displayed a confident and pragmatic demeanor, expressing satisfaction with operational execution and margin expansion amidst a dynamic macro environment. They were notably optimistic about the stabilization of key end markets like polymer processing and automotive, which have been recent headwinds. The tone shifted from defensive regarding past macro challenges to forward-looking and assured about the company's positioning for fiscal 2026.
Confidence: HIGH - Management provided specific guidance ranges, clearly articulated the bottoming of weak markets, and backed their optimism with record financial metrics and strong cash flow data. Their willingness to repurchase shares and provide a bullish outlook on backlog supports high confidence.
1% to 6%
6% to 12%
$630 million to $670 million
$2.25 to $2.45 per share
18.5% to 19.5%
Hedging & Uncertainty: Management employed hedging language primarily around the guidance range and the speed of the market recovery. They frequently used the word 'nominal' to describe expected growth in recovering markets, tempering expectations. For example, CEO Sundaram Nagarajan stated, 'We're expecting nominal growth is what we are expecting in our guide,' and 'we're not expecting any big recovery in our automotive markets.' Regarding the guidance range, CFO Daniel Hopgood described the downside scenario as 'more of a hypothetical,' indicating they are planning for prudence rather than predicting a negative outcome. This suggests confidence in the baseline but caution about the magnitude of the upside.
We have hit the bottom... The recovery seems to be different in these two businesses. - Sundaram Nagarajan, President and CEO
I would say that's more of a hypothetical. - Daniel Hopgood, Executive Vice President and CFO
We're expecting nominal growth... but we're not expecting any big recovery in our automotive markets. - Sundaram Nagarajan, President and CEO
We're going to continue to be balanced in deploying the strong cash that we generate. - Daniel Hopgood, Executive Vice President and CFO
I think it's fair to say that the destocking that was impacting our interventional product lines is now fully behind us. - Daniel Hopgood, Executive Vice President and CFO
Analyst Sentiment: Analysts were generally inquisitive and focused on the sustainability of margins and the specific timing of the recovery in industrial end markets. There was a clear interest in understanding the divergence between strong semiconductor performance and weakness in other areas like x-ray and polymer processing.
Management Responses: Management was responsive and detailed, providing granular color on segment performance. They effectively managed expectations by clarifying that 'nominal' growth is the baseline for recovering markets and that 40% margins in Medical were a notable achievement rather than a new standard.
Discussion on the 'troughing' of polymer processing and automotive markets, with management confirming order entry and backlog are improving but recovery will be gradual.
Inquiry into the sustainability of Medical segment margins (40% in Q4), with management guiding for a normalization to the 'upper 30s'.
Questions regarding the semiconductor cycle and its impact on the ATS segment, specifically the balance between AI-related growth and automotive softness.
Capital allocation strategy, specifically the balance between share buybacks and M&A given the current stock valuation and strong cash flow.
Nordson Corporation presents a compelling investment case driven by its successful execution of the Ascend Strategy, resulting in record profitability and robust free cash flow generation. The company has effectively navigated a challenging macro environment by optimizing its portfolio (divesting lower-margin contract manufacturing) and maintaining strict cost discipline, leading to 32% EBITDA margins. With key headwinds in polymer processing and automotive now stabilizing, and the Medical segment showing strong post-destocking demand, Nordson is poised for a return to growth in fiscal 2026. The strong balance sheet (2.1x leverage) and consistent shareholder returns (buybacks + dividend growth) provide a solid safety margin while the company waits for the industrial cycle to turn. The shift in focus toward 'commercial excellence' suggests there is still room for operational upside as end markets recover.
Management indicated that the severe downturn in polymer processing and automotive markets has bottomed out. CEO Sundaram Nagarajan noted, 'We have hit the bottom,' and stated that these areas should 'no longer be a drag on results heading into the first quarter.' However, the recovery is expected to be 'nominal' rather than a sharp V-shape bounce.
Nordson is benefiting from strong investments in the semiconductor cycle, specifically for AI and cloud computing applications. Management noted that semiconductor applications account for ~50% of ATS revenue and they are 'winning share' in advanced packaging applications.
The destocking cycle that previously impacted interventional product lines has concluded. Management reported 'good, stable demand in our order books' and a return to 'mid-single-digit organic growth' driven by demographic trends like the aging population.